Business
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI NEW HAVEN, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to
About this update from Bioxcel Therapeutics, Inc.
[{"type":"image","alt":"BioXcel Therapeutics","displaySize":"","headline":null,"caption":"BioXcel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":220,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/184443491f4795fadfc360af09172b87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MKdkHmgz4P772UppGCqbJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNQ--/https://media.zenfs.com/en/globenewswire.com/184443491f4795fadfc360af09172b87","width":220,"height":123},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MKdkHmgz4P772UppGCqbJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNQ--/https://media.zenfs.com/en/globenewswire.com/184443491f4795fadfc360af09172b87","width":220,"height":123}},"lazy":false},{"type":"text","content":"FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date ","length":99,"tagName":"p"},{"type":"text","content":"Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia","length":99,"tagName":"p"},{"type":"text","content":"Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI","length":134,"tagName":"p"},{"type":"text","content":"NEW HAVEN, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today provided a business update and reported financial results for the first quarter of 2026. In the quarter ended on March 31, the FDA accepted the Company’s supplemental New Drug Application (sNDA) for IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia and assigned a PDUFA target action date of November 14, 2026.","length":592,"tagName":"p"},{"type":"text","content":"“The first quarter was marked by tremendous progress, achieving a major regulatory milestone and developing the IGALMI commercial launch plan for the at-home setting,” said Vimal Mehta, Ph.D., Chief Executive Officer of BioXcel Therapeutics. “We are very pleased with the recent approval of another product in Alzheimer’s agitation, in an area adjacent to our focus on the acute treatment of agitation in Alzheimer’s dementia with BXCL501. Our first-in-class mechanism ...